Insurance for Houston Biotech Companies

The core program is D&O, clinical trial liability, cyber, and IP indemnity or infringement coverage tied to the licensed platform. Products liability generally does not activate until the company nears commercialization, because there is no marketed product in the hands of patients at the IND or trial stage. Buying meaningful product coverage before then usually spends premium on an exposure the company does not yet carry.

Academic license and sponsored research agreements typically require the company to indemnify the institution and name it as an additional insured, and they often set minimum limits. Those contractual terms drive both the structure and the size of the program, and the policy language has to be matched to the agreement so there is no gap between what the company promised and what the carrier covers. This is one of the most common places a spinout's program falls short if it is bought off the shelf.

D&O becomes necessary once outside investor capital arrives, and limits commonly range from $1M to $15M through Series A to C. As the company adds institutional investors, expands the board, and moves toward an IPO, both the primary limit and the excess structure typically step upward to meet investor and underwriting expectations. The program is usually revisited at each financing round rather than left static.

When a trial runs through a Texas Medical Center hospital or research center, the study operates under that institution's insurance, indemnity, and IRB framework. The sponsoring biotech generally has to align its clinical trial liability coverage with those terms, provide evidence of coverage, and accept additional-insured and indemnification provisions in the clinical trial agreement. Clinical trial liability is sized per active trial so that coverage reflects the specific protocols and sites involved.